

ACHIEVE LIFE SCIENCES INC.

INVESTOR OVERVIEW

SUMMARY

52-Week High	\$	18.26
52-Week Low	\$	6
Fully Diluted Shares		6.1M
Volume (Weekly)		1.5M

FINANCIAL STATEMENT OVERVIEW

Cash (\$M)	\$	36M
Debt (\$M)	\$	NA
Currency		\$US
Warrants/Options		
Next Year Revenue		Minus \$3.76
Insiders %		2%
Peer		Pfizer

TOP SHAREHOLDERS

Francis Capital Management LLC
Globis Capital Management LLP
Ikarian Capital LLC
CVI Investments Inc.
Pura Vida Investments

OPERATIONAL & CORPORATE OVERVIEW

CORPORATE FOCUS

Primary Focus	Pharma Development
Broker Coverage	Maxim, Lake Street, Ladenburg, HC Wainwright, Zacks
Main Asset 1	Cytisinicline
Main Asset 2	
Main Asset 3	

SENIOR MANAGEMENT

CEO	John A. Bencich
IR	Jason Wong
Investor Relations (Email)	jwong@bplifescience.com
Headquarters	Seattle
Website	www.achievelifesciences.com

Independent Investment Research (IIR) accepts no responsibility for any error or omission in content produced in good faith from reliable sources. There is no solicitation to buy or sell securities. Advice is not offered or implied. Users must seek their own suitable advice. IIR may receive fees for production of research. IIR and its employees are indemnified by the user of content for any damages express or implied.

NASDAQ:ACHV

Last Updated: 5/04/2021

Achieve Life Sciences is a specialty pharmaceutical company committed to advancing cytisinicline as a smoking cessation aid to address the global tobacco and nicotine addiction epidemic. Cytisinicline (also known as cytisine) is a plant-based alkaloid with a high binding affinity to the $\alpha 4\beta 2$ nicotine receptor.



ANALYST COMMENT

Growing confidence in a replacement for the expiring Pfizer anti smoking drug plus a successful New Zealand clinical trial have lifted prospects for Achieve. Institutional holders have increased from 9 to 15 in the December quarter.

CONTACT INFORMATION

Produced and Edited by Independent Investment Research LLC
John Kimber 720-355-0446

